German HTA joins critics on WHO trial data disclosure shortcomings
This article was originally published in SRA
Executive Summary
The World Health Organization has faced more criticism that its statement on disclosing clinical trial data does not go far enough if it really wants to make a difference – this time from Germany's health technology appraisal body, IQWiG. Among other things, the WHO needs to work out how it will make organizations comply with its demands, says the IQWiG1.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.